This historical review outlines the discovery, development, and post-marketing surveillance of captopril, highlighting its foundational role and sustained efficacy in managing hypertension and heart failure.
Answers are grounded in this paper and cite their sources.
Offers no new clinical guidance on captopril; leaves open value of historical reviews for future drug design.
Captopril, the first angiotensin-converting enzyme (ACE) inhibitor was discovered through random screening of 2,000 chemical structures, by E. R. Squibb and Sons Pharmaceuticals. Then patented and developed 1980, to the marketed product Capoten. At a daily dose of 400-1000 mg, the drug showed significant anti-hypertensive activity in patients through enhancing plasma rennin activity, decreasing aldosterone in plasma and elimination of ACE activity. Dose was decreased to 50-150 mg/day after drug resistance was recognized in first 200 patients treated with captopril at the initial dose. Captopril pharmacodynamics and pharmacokinetics parameters were established through continuous clinical trials in human subjects. Initial post-marketing study found it safe and effective for treatment of mild hypertension and early cardiac failure. However, recent studies reveal different adverse events in hypertensive patients treated with captopril.
No takes yet. Share an insight, caveat, or question.
El‐Haj et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: